Oncotype DX Breast Cancer Testing
Oncotype DX is a validated genomic assay recommended by NICE (DG34) for guiding chemotherapy decisions in specific cohorts of early breast cancer. It provides a Recurrence Score that stratifies patients into groups where chemotherapy is beneficial versus where endocrine therapy alone is sufficient. Additional information: This is a call off contract from framework 2023/S 000-028831 based on previous contracts usage.
Buyer
East Sussex Healthcare NHS Trust
Value
£272,700
Published
3 Mar 2026
Closes
4 Feb 2026
Procurement details
Source
Contracts Finder
Region
United Kingdom
Procurement method
Selective
Category
Services
Contract starts
31 Mar 2026
Contract ends
31 Mar 2027
CPV classifications
85111800
Pathology services
Lots
Lot default Oncotype DX Breast Cancer Testing
£272,700
Oncotype DX is a validated genomic assay recommended by NICE (DG34) for guiding chemotherapy decisions in specific cohorts of early breast cancer. It provides a Recurrence Score that stratifies patients into groups where chemotherapy is beneficial versus where endocrine therapy alone is sufficient. Additional information: This is a call off contract from fra...
Delivery: United Kingdom
Documents
Unlock document linkAwarded contract notice on Contracts Finder
3 Mar 2026
Awarded contract notice on Contracts Finder
Award notice · Web page
Contains public sector information licensed under the Open Government Licence v3.0.